Laurie Barclay, MD Oct. 21, 2002
Estrogen-replacement therapy (ERT) may be given two years after women are disease-free from estrogen receptor (ER)-negative early-stage breast carcinoma, or after 10 years if ER status was unknown.
Results of a five-year prospective trial reported in the Nov. 1 issue of Cancer showed that women meeting these criteria were not harmed by starting ERT, but the investigators suggest that larger randomized trials are needed to confirm these findings. This study “provides prospective data with much longer follow-up than previous series and reinforced the notion that ERT does not compromise disease-free states in patients with curatively treated breast cancer,” write Rena Vassilopoulou-Sellin, MD, and colleagues from the M.D. Anderson Cancer Center in Houston, Texas
תגובות רוצה להצטרף לדיון?
יש להתחבר כדי להגיב.
התחבראין תגובות עדיין. היה הראשון להגיב!